Bridgebio Announces Publication In The New England Journal Of Medicine Of Phase 3 PROPEL 3 Trial Of Oral Infigratinib In Children Living With Achondroplasia

(MENAFN - GlobeNewsWire - Nasdaq) - Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span ...